Spero Therapeutics announced the appointment of Melissa Stundick, Ph.D., to the newly created leadership position of Head of Strategic Alliances. In her new post, Dr. Stundick will navigate partnerships between the company and other pharmaceutical, biopharmaceutical and government entities, and set objectives for collaborations. In addition, she will identify new opportunities as part of the company's ongoing efforts to create novel treatments to combat antibiotic resistance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | +3.81% |
|
+10.70% | +2.04% |
07-01 | Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell 3000E Growth Index | CI |
07-01 | Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell Microcap Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.04% | 80.98M | |
+20.17% | 126B | |
+24.67% | 118B | |
+22.85% | 27.87B | |
-17.74% | 20.95B | |
-15.94% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics Appoints Melissa Stundick as Head of Strategic Alliances